A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
NCT ID: NCT01752491
Last Updated: 2024-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
13 participants
INTERVENTIONAL
2013-04-01
2019-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Standard treatment for glioblastoma multiforme (GBM) involves surgery followed by radiation combined with temozolomide (a chemotherapy). After radiation, patients receive cycles of temozolomide (adjuvant chemotherapy)
Participants will:
* receive high doses of intravenous (IV) ascorbate three times a week during chemoradiation
* receive high doses of intravenous (IV) ascorbate twice a week during adjuvant chemotherapy (after radiation)
This is a phase 1 study will evaluate the side effects of adding this drug to the standard therapy. The dose given to a participant will be determined by how well other participants have tolerated the drug.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
15g Ascorbate
During radiation therapy:
* Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks.
* Temozolomide: 75 mg/m2, taken orally, once daily, every day, until radiation is completed.
* Ascorbate: 15 g administered by IV three times a week until 1 month after radiation is completed (approximately 12 weeks).
After radiation therapy:
* Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
* Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months.
Ascorbate
Intravenous infusion of high-dose ascorbate
Temozolomide
Oral chemotherapeutic
Radiation therapy
External beam radiation therapy
25g Ascorbate
If the 15g arm is tolerated, the study opens the 25g arm.
During radiation therapy:
* Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.
* Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.
* Ascorbate: 25 g administered by IV three times/wk until 1 month after radiation is completed (about 12 weeks).
After radiation therapy:
* Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
* Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months.
Ascorbate
Intravenous infusion of high-dose ascorbate
Temozolomide
Oral chemotherapeutic
Radiation therapy
External beam radiation therapy
50g arm
If the 25g arm is tolerated, the study opens the 50g arm.
During radiation therapy:
* Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.
* Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.
* Ascorbate: 50 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).
After radiation therapy:
* Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
* Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months.
Ascorbate
Intravenous infusion of high-dose ascorbate
Temozolomide
Oral chemotherapeutic
Radiation therapy
External beam radiation therapy
62.5g
If the 50g arm is tolerated, the study opens the 62.5g arm.
During radiation therapy:
* Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.
* Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.
* Ascorbate: 62.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).
After radiation therapy:
* Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
* Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months.
Ascorbate
Intravenous infusion of high-dose ascorbate
Temozolomide
Oral chemotherapeutic
Radiation therapy
External beam radiation therapy
75g Ascorbate
If the 62.5g arm is tolerated, the study opens the 75g arm.
During radiation therapy:
* Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.
* Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.
* Ascorbate: 75 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).
After radiation therapy:
* Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
* Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months.
Ascorbate
Intravenous infusion of high-dose ascorbate
Temozolomide
Oral chemotherapeutic
Radiation therapy
External beam radiation therapy
87.5g Ascorbate
If the 75g arm is tolerated, the study opens the 87.5g arm.
During radiation therapy:
* Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.
* Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.
* Ascorbate: 87.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).
After radiation therapy:
* Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
* Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months.
Ascorbate
Intravenous infusion of high-dose ascorbate
Temozolomide
Oral chemotherapeutic
Radiation therapy
External beam radiation therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ascorbate
Intravenous infusion of high-dose ascorbate
Temozolomide
Oral chemotherapeutic
Radiation therapy
External beam radiation therapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis must be made by surgical biopsy or excision.
* Therapy must begin ≤ 5 weeks after surgery.
* Age ≥ 18 years
* ECOG performance status 0-2 (Karnofsky \> 50%).
* A complete blood count and differential must be obtained within 21 days prior to the first dose of radiation, with adequate bone marrow functions as defined below:
* Absolute neutrophil count (ANC) ≥ 1500 cells per mm3
* Platelets ≥ 100,000 per mm3
* Hemoglobin ≥ 8 g/dL
* Serum blood chemistries within 21 days before the first day of radiation, as defined below:
* Creatinine ≤ 2.0 mg
* Total bilirubin ≤ 1.5 mg/dL
* ALT (Alanine Aminotransferase)≤ 3 times the institutional upper limit of normal
* AST (Aspartate Aminotransferase) ≤ 3 times the institutional upper limit of normal
* Tolerate one text dose (15g) of ascorbate
* Not pregnant
* Ability to understand and willingness to sign a written informed consent document
Exclusion Criteria
* G6PD (glucose-6-phosphate dehydrogenase) deficiency
* Patients actively receiving insulin unless approved by the study medical monitor, study sponsor, and the study principal investigator.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide.
* Significant co-morbid central nervous system disease, including but not limited to, multiple sclerosis.
* Patients who are on the following drugs and cannot have a drug substitution: flecainide, methadone, amphetamines, quinidine, and chlorpropamide. High dose ascorbic acid may affect urine acidification and, as a result, may affect clearance rates of these drugs.
* Prior invasive malignancies (except non-melanomatous skin cancers and carcinoma in situ of the cervix or bladder) unless disease free for ≥ 5 years.
* Patients who have received prior chemotherapy (including Gliadel wafers) for the current glioma.
* Prior radiation therapy to the head or neck, which would result in overlap of radiation therapy fields.
* Patients may not be receiving any other investigational agents.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Pregnant women are excluded from this study because ionizing radiation is a known teratogen, and temozolomide is a Class D agent with the potential for teratogenic or abortifacient effects.
* Known HIV-positive individuals. High-dose ascorbate acid is a known CYP450 3A4 (an enzyme pathway) inducer, which results in lower serum levels of antiretroviral drugs
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
National Cancer Institute (NCI)
NIH
Joseph J. Cullen, MD, FACS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John M. Buatti
Professor and Chair, Department of Radiation Oncology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John M. Buatti, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Radiation Oncology, The University of Iowa
Joseph J Cullen, MD
Role: STUDY_DIRECTOR
Professor of Surgery, The University of Iowa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Holden Comprehensive Cancer Center at the University of Iowa
Iowa City, Iowa, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Du J, Cullen JJ, Buettner GR. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta. 2012 Dec;1826(2):443-57. doi: 10.1016/j.bbcan.2012.06.003. Epub 2012 Jun 20.
Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, Taghiyev AF, Du C, Knudson CM, Cullen JJ. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res. 2010 Jan 15;16(2):509-20. doi: 10.1158/1078-0432.CCR-09-1713. Epub 2010 Jan 12.
Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.